Revenue Recognition and Deferred Revenue [Abstract]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
Revenue Recognition, Milestone Method, Undelivered Element [Axis]
Revenue Recognition, Undelivered Element [Axis]
Revenue Recognition, Undelivered Element [Axis]
Revenue Recognition, Milestone Method, Undelivered Element [Domain]
Revenue Recognition, Milestone Method, Undelivered Element [Domain]
[Domain] for Revenue Recognition, Milestone Method, Undelivered Element [Axis]
Program Licenses
Program Licenses [Member]
Program Licenses [Member]
On-going development services (principal)
On-Going Development Services, Principal [Member]
On-Going Development Services, Principal [Member]
On-going research and development
On-Going Research And Development [Member]
On-Going Research And Development [Member]
Committee participations
Committee Participations [Member]
Committee Participations [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Type of Arrangement and Non-arrangement Transactions [Axis]
Arrangements and Non-arrangement Transactions [Domain]
Arrangements and Non-arrangement Transactions [Domain]
AG-881 program licenses
Ag 881 Agreements [Member]
Ag 881 agreements.
Collaborative arrangement, product
Collaborative Arrangement, Product [Member]
Modification Period [Axis]
Modification Period [Axis]
Modification Period [Axis]
Modification Period [Domain]
Modification Period [Domain]
[Domain] for Modification Period [Axis]
April 2015 modification
April 2015 [Member]
April 2015 [Member]
May 2016 modification (supplants undelivered elements of April 2015 modification)
May 2016 [Member]
May 2016 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue – related party
Revenues
Range [Axis]
Range [Axis]
Range [Domain]
Range [Domain]
Minimum
Minimum [Member]
Counterparty Name [Axis]
Counterparty Name [Axis]
Counterparty Name [Domain]
Counterparty Name [Domain]
Celgene
Celgene [Member]
Celgene.
2016 Agreement
Master Research And Collaboration Agreement [Member]
Master research and collaboration agreement.
Initial payment received
Deferred Revenue, Additions
Extension period
Revenue Recognition, Multiple-deliverable Arrangements, Extension Term
Revenue Recognition, Multiple-deliverable Arrangements, Extension Term
Number of allowable special case extensions
Revenue Recognition, Multiple-deliverable Arrangements, Number Of Special Case Extensions
Revenue Recognition, Multiple-deliverable Arrangements, Number Of Special Case Extensions
Upfront payment agreement extension fee receivable
Upfront Payment Agreement Extension Fee Receivable
Upfront payment agreement extension fee receivable.
Option exercise fee receivable
Option Exercise Fee Receivable
Option exercise fee receivable
Minimum option exercise fee receivable for continuation program
Option Exercise Fee Receivable For Continuation Program
Option exercise fee receivable for continuation program.
Additional option exercise fee for further development
Additional Option Exercise Fee Receivable
Additional option exercise fee receivable.
Collaboration Agreements
Collaborative Arrangement Disclosure [Text Block]
Payables and Accruals [Abstract]
Accrued Expenses
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Award Type [Axis]
Award Type [Axis]
Equity Award [Domain]
Equity Award [Domain]
Restricted stock units
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested shares beginning of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Vested (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Forfeited/expired (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Unvested shares end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-average grant date fair value, Unvested shares beginning of period (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Granted (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Vested (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Forfeited/expired (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value, Unvested shares end of period (in usd per share)
Master Research And Collaboration Agreement
2010 Agreement
Agreement 2010 [Member]
Agreement 2010 [Member]
Products and Services [Axis]
Products and Services [Axis]
Products and Services [Domain]
Products and Services [Domain]
IDHIFA
IDHIFA [Member]
IDHIFA [Member]
Total collaboration revenue
Revenue Recognition, Milestone Method, Revenue Recognized
Milestone payments upon achievement of specified regulatory milestone events
Portion Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Events Program
Portion of potential milestone payment receivable for specified regulatory milestone events program.
Summary of Company's Stock Option Activity
Share-based Compensation, Stock Options, Activity [Table Text Block]
Unvested Stock Unit Activity
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]
Schedule of Performance-Based Units
Schedule of Nonvested Performance-based Units Activity [Table Text Block]
Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]
Summary of Allocated Stock-Based Compensation Expense
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Statement of Financial Position [Abstract]
Preferred stock, par value (in usd per share)
Preferred Stock, Par or Stated Value Per Share
Preferred stock, shares authorized (in shares)
Preferred Stock, Shares Authorized
Preferred stock, shares issued (in shares)
Preferred Stock, Shares Issued
Preferred stock, shares outstanding (in shares)
Preferred Stock, Shares Outstanding
Common stock, par value (in usd per share)
Common Stock, Par or Stated Value Per Share
Common stock, shares authorized (in shares)
Common Stock, Shares Authorized
Common stock, shares issued (in shares)
Common Stock, Shares, Issued
Common stock, shares outstanding (in shares)
Common Stock, Shares, Outstanding
Earnings Per Share [Abstract]
Loss per Share
Earnings Per Share [Text Block]
On-going development services (agent)
On-Going Development Services, Agent [Member]
On-Going Development Services, Agent [Member]
Additional development services
Additional Development Services [Member]
Additional Development Services [Member]
Revenue Recognition, Multiple-deliverable Arrangements, Recognition Period [Axis]
Revenue Recognition, Multiple-deliverable Arrangements, Recognition Period [Axis]
Revenue Recognition, Multiple-deliverable Arrangements, Recognition Period [Axis]
Revenue Recognition, Multiple-deliverable Arrangements, Recognition Period [Domain]
Revenue Recognition, Multiple-deliverable Arrangements, Recognition Period [Domain]
[Domain] for Revenue Recognition, Multiple-deliverable Arrangements, Recognition Period [Axis]
Upon Execution of Agreement
Upon Execution of Agreement [Member]
Upon Execution of Agreement [Member]
Upon delivery of the licenses to Celgene, which occurred immediately upon the execution of the AG-881 Agreements
Recognition Period One [Member]
Recognition Period One [Member]
Proportionally as services are delivered over the performance period, expected to be through September 2017
Recognition Period Two [Member]
Recognition Period Two [Member]
Ratably over the performance period, expected to be through April 2016
Recognition Period Eight [Member]
Recognition Period Eight [Member]
Proportionally as services are delivered over the performance period, expected to be through December 2019
Recognition Period Five [Member]
Recognition Period Five [Member]
Ratably over the performance period, expected to be through December 2016
Recognition Period Three [Member]
Recognition Period Three [Member]
Proportionally as services are delivered over the performance period, expected to be through 2019
Recognition Period Four [Member]
Recognition Period Four [Member]
Ratably over the performance period, expected to be through May 2022
Recognition Period 8 [Member]
Recognition Period 8 [Member]
Ratably over the performance period, expected to be through December 2022
Recognition Period Six [Member]
Recognition Period Six [Member]
Proportionally as services are delivered over the performance period, expected to begin in September 2020
Recognition Period Seven [Member]
Recognition Period Seven [Member]
Best estimate selling price (BESP)
Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount
Unit(s) of Accounting
Revenue Recognition, Multiple-deliverable Arrangements, Units Of Accounting
Revenue Recognition, Multiple-deliverable Arrangements, Units Of Accounting
Assets
Assets [Abstract]
Current assets:
Assets, Current [Abstract]
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Marketable securities
Available-for-sale Securities, Current
Collaboration receivable – related party
Collaboration Receivable, Due from Related Parties, Current
Collaboration Receivable, Due from Related Parties, Current
Royalty receivable – related party
Royalty Receivable, Due from Related Parties, Current
Royalty Receivable, Due from Related Parties, Current
Tenant improvement and other receivables
Accounts and Other Receivables, Net, Current
Prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Total current assets
Assets, Current
Marketable securities
Available-for-sale Securities, Noncurrent
Property and equipment, net
Property, Plant and Equipment, Net
Other non-current assets
Other Assets, Noncurrent
Total assets
Assets
Liabilities and stockholders’ equity
Liabilities and Equity [Abstract]
Current liabilities:
Liabilities, Current [Abstract]
Accounts payable
Accounts Payable, Current
Accrued expenses
Accrued Liabilities, Current
Deferred revenue – related party
Deferred Revenue, Current
Deferred rent
Deferred Rent Credit, Current
Total current liabilities
Liabilities, Current
Deferred revenue, net of current portion – related party
Deferred Revenue, Noncurrent
Deferred rent, net of current portion
Deferred Rent Credit, Noncurrent
Total liabilities
Liabilities
Stockholders’ equity:
Stockholders' Equity Attributable to Parent [Abstract]
Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at September 30, 2017 and December 31, 2016
Preferred Stock, Value, Issued
Common stock, $0.001 par value; 125,000,000 shares authorized; 48,617,989 and 42,220,444 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively
Common Stock, Value, Issued
Additional paid-in capital
Additional Paid in Capital, Common Stock
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Total stockholders’ equity
Stockholders' Equity Attributable to Parent
Total liabilities and stockholders’ equity
Liabilities and Equity
Milestone-based receivable payments, eligible to be received
Revenue Recognition, Milestone Method, Eligible Receivable
Revenue Recognition, Milestone Method, Eligible Receivable
Milestone payment for filing of first NDA
Portion Of Potential Milestone Payment Receivable For Filing Of New Drug Application
Portion of potential milestone payment receivable for filing of new drug application.
Summary of Accrued Expenses
Schedule of Accrued Liabilities [Table Text Block]
Investments, Debt and Equity Securities [Abstract]
Marketable Securities
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Schedule of Milestone-Based Payments Associated With 2016 Agreement
Revenue Recognition, Milestone Method [Table Text Block]
Summary of Multiple-deliverable Arrangements Revenue
Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Overview and Basis of Presentation
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Income Statement [Abstract]
Reduction of research and development expenses
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned
Fair Value Disclosures [Abstract]
Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Statement of Cash Flows [Abstract]
Operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net loss
Net Income (Loss) Attributable to Parent
Adjustments to reconcile net loss cash (used in) provided by operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation
Depreciation
Stock-based compensation expense
Share-based Compensation
Net amortization of premium and discounts on investments
Accretion (Amortization) of Discounts and Premiums, Investments
Loss on disposal of property and equipment
Gain (Loss) on Disposition of Assets
Changes in operating assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Collaboration receivable – related party
Increase (Decrease) in Collaboration Receivable, Due from Related Parties, Current
Increase (Decrease) in Collaboration Receivable, Due from Related Parties, Current
Royalty receivable – related party
Increase (Decrease) in Royalty Receivable, Due from Related Parties, Current
Increase (Decrease) in Royalty Receivable, Due from Related Parties, Current
Tenant improvement and other receivables
Increase (Decrease) in Accounts and Other Receivables
Prepaid expenses and other current and non-current assets
Increase (Decrease) in Prepaid Expense and Other Assets
Accounts payable
Increase (Decrease) in Accounts Payable
Accrued expenses
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Deferred revenue – related party
Increase (Decrease) in Deferred Revenue
Deferred rent
Increase (Decrease) in Deferred Charges
Net cash (used in) provided by operating activities
Net Cash Provided by (Used in) Operating Activities
Investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]
Purchases of marketable securities
Payments to Acquire Available-for-sale Securities
Proceeds from maturities and sales of marketable securities
Proceeds from Sale and Maturity of Available-for-sale Securities
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities
Financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]
Payment of public offering costs, net of reimbursements
Payments of Stock Issuance Costs
Proceeds from public offering of common stock, net of commissions
Proceeds from Issuance of Common Stock
Net proceeds from stock option exercises and employee stock purchase plan
Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Net change in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Cash and cash equivalents at beginning of the period
Cash and cash equivalents at end of the period
Supplemental disclosure of non-cash investing and financing transactions
Noncash Investing and Financing Items [Abstract]
Additions to property and equipment in accounts payable and accrued expenses
Capital Expenditures Incurred but Not yet Paid
Proceeds from stock option exercises in other receivables
Proceeds From Stock Options Exercised In Other Current Assets
Proceeds receivable from stock options exercised in other current assets.
Public offering costs in other receivables, net of amounts in accounts payable and accrued expenses
Public Offering Costs In Other Current Assets
Public Offering Costs In Other Current Assets
Fair Value, by Balance Sheet Grouping [Table]
Fair Value, by Balance Sheet Grouping [Table]
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurements, Recurring
Fair Value, Measurements, Recurring [Member]
Fair Value, Hierarchy [Axis]
Fair Value, Hierarchy [Axis]
Fair Value Hierarchy [Domain]
Fair Value Hierarchy [Domain]
Level 1
Fair Value, Inputs, Level 1 [Member]
Level 2
Fair Value, Inputs, Level 2 [Member]
Level 3
Fair Value, Inputs, Level 3 [Member]
Investment Type [Axis]
Investment Type [Axis]
Investments [Domain]
Investments [Domain]
Certificates of deposit
Certificates of Deposit [Member]
U.S. Treasuries
US Treasury Securities [Member]
Government securities
US Government Corporations and Agencies Securities [Member]
Corporate debt securities
Corporate Debt Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Marketable securities
Available-for-sale Securities
Total cash equivalents and marketable securities
Cash Equivalents And Available For Sale Securities
Cash equivalents and available for sale securities.
Marketable Securities
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]
Accounting Policies [Abstract]
Basis of presentation
Basis of Accounting, Policy [Policy Text Block]
Significant accounting policies and Recent accounting pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Fair Value Measurements
Fair Value Measurement, Policy [Policy Text Block]
Marketable Securities
Marketable Securities, Policy [Policy Text Block]
Collaboration Revenue
Revenue Recognition, Multiple-deliverable Arrangements, Description [Policy Text Block]
Loss per Share
Earnings Per Share, Policy [Policy Text Block]
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited [Member]
Aurigene Discovery Technologies Limited [Member]
Upfront payment
Research and Development Expense
Potential future milestone payments
Research and Development Arrangement, Contract to Perform for Others, Potential Milestone Payable
Research and Development Arrangement, Contract to Perform for Others, Potential Milestone Payable
Revenue Recognition, Milestone Method [Table]
Revenue Recognition, Milestone Method [Table]
Specified clinical development event
Clinical Development Event [Member]
Clinical development event.
Specified regulatory milestone events
Regulatory Milestone Events [Member]
Regulatory milestone events.
Specified commercial milestone events
Commercial Milestone Events [Member]
Commercial milestone events.
Maximum
Maximum [Member]
Project [Axis]
Project [Axis]
Project [Domain]
Project [Domain]
65/35 Program
Program One [Member]
Program one.
Other Than 65/35 Program
Program Two [Member]
Program two.
Co-Development and Co-Commercialization Agreements
Co-development and Co-commercialization Agreements [Member]
Co-development and co-commercialization agreements.
Co Commercial Agreement
Co Commercial Agreement [Member]
Co-commercial agreement.
Revenue Recognition, Milestone Method [Line Items]
Revenue Recognition, Milestone Method [Line Items]
Accrued compensation
Employee-related Liabilities, Current
Accrued research and development costs
Accrued Research And Development Costs Current
Accrued research and development costs current.
Accrued professional fees
Accrued Professional Fees, Current
Accrued other
Other Accrued Liabilities, Current
Total
Plan Name [Axis]
Plan Name [Axis]
Plan Name [Domain]
Plan Name [Domain]
2007 Plan and 2013 Plan
Two Thousand Seven Stock Incentive Plan And Two Thousand Thirteen Stock Incentive Plan [Member]
Two Thousand Seven Stock Incentive Plan And Two Thousand Thirteen Stock Incentive Plan [Member]
2013 Stock Incentive Plan
Two Thousand And Thirteen Stock Incentive Plan [Member]
Two thousand and thirteen stock incentive plan.
2013 Employee Stock Purchase Plan
Employee Stock Purchase Plan 2013 [Member]
Employee Stock Purchase Plan 2013 [Member]
Performance-based stock options
Performance Shares [Member]
Performance-Based Stock Units (PSUs)
Performance Stock Unit [Member]
Performance Stock Unit [Member]
Common stock reserved for issuance (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Shares available for future issuance (in shares)
Common Stock, Capital Shares Reserved for Future Issuance
Total unrecognized compensation expense related to stock option
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options
Weighted-average period to recognize compensation expense (in years)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition
Stock options granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Purchase price discount rate stock option
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent
Shares issued under 2013 ESPP (in shares)
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Opportunity to purchase of common stock (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee
Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]
Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]
Sale of Stock [Axis]
Sale of Stock [Axis]
Sale of Stock [Domain]
Sale of Stock [Domain]
Public Offering
Public Offering [Member]
Public offering.
Over-Allotment Option
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued from public offering (in shares)
Stock Issued During Period, Shares, New Issues
Offer price (in usd per share)
Shares Issued, Price Per Share
Income Statement Location [Axis]
Income Statement Location [Axis]
Income Statement Location [Domain]
Income Statement Location [Domain]
Research and development expense
Research and Development Expense [Member]
Total reduction of research and development expenses
Reimbursement Revenue
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Stock options
Employee Stock Option [Member]
Employee Stock Purchase Plan options
Employee Purchase Plan [Member]
Employee Purchase Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Collaboration revenue – related party
License and Services Revenue
Royalty revenue – related party
Royalty Revenue
Total revenue
Operating expenses:
Operating Expenses [Abstract]
Research and development (net of $2,776 and $8,794 of cost reimbursement from related party for the three months ended March 31, 2017 and 2016, respectively)
General and administrative
General and Administrative Expense
Total operating expenses
Operating Expenses
Loss from operations
Operating Income (Loss)
Interest income
Investment Income, Interest
Net loss
Net (loss) income per share – basic and diluted (usd per share)
Earnings Per Share, Basic and Diluted
Weighted-average number of common shares used in computing net (loss) income per share – basic and diluted (in shares)
Weighted Average Number of Shares Outstanding, Basic and Diluted
Document And Entity Information [Abstract]
Document and entity information.
Entity Registrant Name
Entity Registrant Name
Trading Symbol (Optional DEI Element)
Trading Symbol
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Filer Category
Entity Filer Category
Document Type
Document Type
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Milestone payment upon achievement of a specified commercial milestone event
Portion Of Potential Milestone Payment Receivable For Specified Commercial Milestone Event Program
Portion of potential milestone payment receivable for specified commercial milestone event program.
Royalty revenue
Common Stock Excluded from Calculation of Diluted Earnings Per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Legal Entity [Axis]
Legal Entity [Axis]
Entity [Domain]
Entity [Domain]
Number of cancer metabolism programs discovered under previous agreement, now governed by current agreement
Revenue Recognition, Multiple-deliverable Arrangements, Number Of Programs Discovered Under Previous Agreement, Now Governed By Current Agreement
Revenue Recognition, Multiple-deliverable Arrangements, Number Of Programs Discovered Under Previous Agreement, Now Governed By Current Agreement
Initial research term
Revenue Recognition, Multiple-deliverable Arrangements, Term Of Agreement
Revenue Recognition, Multiple-deliverable Arrangements, Term Of Agreement
Special case extension term
Revenue Recognition, Multiple-deliverable Arrangements, Special Case Extension Term
Revenue Recognition, Multiple-deliverable Arrangements, Special Case Extension Term
Number of programs that may be designated for continued development for which development candidates have yet to be nominated
Revenue Recognition, Multiple-deliverable Arrangements, Number Of Research Programs That Can Be Designated For Continued Development After The Research Term
Revenue Recognition, Multiple-deliverable Arrangements, Number Of Research Programs That Can Be Designated For Continued Development After The Research Term
Not Included In Modification Due To High Level Of Uncertainty
Not Included In Modification Due To High Level Of Uncertainty [Member]
Not Included In Modification Due To High Level Of Uncertainty [Member]
Development Activities
Development Activities [Member]
Development Activities [Member]
Commercial Activities
Commercial Activities [Member]
Commercial Activities [Member]
Collaboration revenue - related party
Revenue from Related Parties
Collaboration receivable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Stock Options, Outstanding, Beginning balance (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Number of Stock Options, Granted (in shares)
Number of Stock Options, Exercised (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Number of Stock Options, Forfeited/Expired (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Number of Stock Options, Outstanding, Ending balance (in shares)
Number of Stock Options, Exercisable (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Number of Stock Options, Vested and expected to vest (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-Average Exercise Price, Outstanding, Beginning balance (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted-Average Exercise Price, Granted (in usd per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Weighted-Average Exercise Price, Exercised (in usd per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted-Average Exercise Price, Forfeited/Expired (in usd per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Weighted-Average Exercise Price, Outstanding, Ending balance (in usd per share)
Weighted-Average Exercise Price, Exercisable (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Weighted-Average Exercise Price, Vested and expected to vest (in usd per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Summary of Significant Accounting Policies and Recent Accounting Pronouncements
Significant Accounting Policies [Text Block]
Share-Based Payments
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Schedule of Available-for-sale Securities [Table]
Schedule of Available-for-sale Securities [Table]
Balance Sheet Location [Axis]
Balance Sheet Location [Axis]
Balance Sheet Location [Domain]
Balance Sheet Location [Domain]
Current:
Current Asset [Member]
Current asset.
Non-current:
Non Current Assets [Member]
Non current assets.
Schedule of Available-for-sale Securities [Line Items]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost
Available-for-sale Securities, Amortized Cost Basis
Unrealized Gains
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax
Unrealized Losses
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax
Fair Value
Realized gain loss) on marketable securities
Marketable Securities, Realized Gain (Loss)
Reclassifications out of accumulated other comprehensive income
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax
Minimum maturity (in years)
Available For Sale Securities Current Maturity Period
Available for sale securities current maturity period.
Maximum maturity (in years)
Available For Sale Securities Non Current Maturity Period
Available for sale securities non current maturity period.
Established time period for liquidation
Available For Sale Securities Non Current Minimum Liquidating Period
Available for sale securities non current minimum liquidating period.
Debt securities in an unrealized loss position
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Greater than or Equal to One Year
Aggregate fair value of debt securities in an unrealized loss position
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
General and administrative expense
General and Administrative Expense [Member]
Total stock-based compensation expense
Allocated Share-based Compensation Expense
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Transfers of assets from Level 1 to Level 2
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount
Transfers of assets from Level 2 to Level 1
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount
Transfers of liabilities from Level 1 to Level 2
Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount
Transfers of liabilities from Level 2 to Level 1
Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount
Fair value of assets (liabilities)
Fair Value, Net Asset (Liability)
Employee Stock Purchase Plan
Employee Stock Purchase Plan [Member]
Employee Stock Purchase Plan [Member]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Profit or loss share percentage
Profit Loss Share Percentage
Profit loss share percentage.
Statement of Comprehensive Income [Abstract]
Other comprehensive income (loss)
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Unrealized gain (loss) on available-for-sale securities
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax
Comprehensive loss
Comprehensive Income (Loss), Net of Tax, Attributable to Parent